U.S. markets open in 7 hours 10 minutes
  • S&P Futures

    3,825.50
    0.00 (0.00%)
     
  • Dow Futures

    30,930.00
    -3.00 (-0.01%)
     
  • Nasdaq Futures

    11,685.75
    +11.50 (+0.10%)
     
  • Russell 2000 Futures

    1,737.80
    -0.50 (-0.03%)
     
  • Crude Oil

    111.42
    -0.34 (-0.30%)
     
  • Gold

    1,822.00
    +0.80 (+0.04%)
     
  • Silver

    20.79
    -0.02 (-0.08%)
     
  • EUR/USD

    1.0496
    -0.0029 (-0.27%)
     
  • 10-Yr Bond

    3.2060
    0.0000 (0.00%)
     
  • Vix

    28.36
    +1.41 (+5.23%)
     
  • GBP/USD

    1.2190
    +0.0005 (+0.04%)
     
  • USD/JPY

    135.9800
    -0.1480 (-0.11%)
     
  • BTC-USD

    20,116.98
    -708.31 (-3.40%)
     
  • CMC Crypto 200

    435.16
    -14.91 (-3.31%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    26,804.60
    -244.87 (-0.91%)
     

Cocrystal Pharma Stock Gains After Laying Out Plans To Launch Another COVID-19 Antiviral Candidate

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Cocrystal Pharma Inc (NASDAQ: COCP) has announced progress on its COVID-19 antiviral drug candidates that target coronaviruses, including SARS-CoV-2, and it also plans to launch a second COVID-19 program with additional antiviral compounds for development, apart from CDI-45205.

  • The company said that it had designed new chemical scaffolds to improve in vitro potency and pharmacokinetic properties. Lead discovery and optimization are ongoing.

  • Identification of another SARS-CoV-2 preclinical lead for oral administration is anticipated this year.

  • Additionally, the company is also developing novel SARS-CoV-2 inhibitors that block viral replication and transcription.

  • In December last year, Cocrystal selected CDI-45205 as its lead coronavirus development candidate, obtained under an exclusive license agreement with Kansas State University Research Foundation (KSURF).

  • CDI-45205 showed good bioavailability in mouse and rat pharmacokinetic studies via intraperitoneal injection and no cytotoxicity against various human cell lines. The company recently demonstrated a strong synergistic effect with the FDA-approved COVID-19 medicine remdesivir.

  • Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-2 infected mice.

  • Price Action: COCP shares are up 0.85% at $1.19 on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.